Особенности лечения артериальной гипертензии у пациентов пожилого возраста


Д.А. Напалков 1, Е.Н. Головенко 2

1. Первый МГМУ им. И.М. Сеченова, Москва; 2. ФГУ “Эндокринологический научный центр” Минздравсоцразвития России, Москва
Обсуждается стратегия профилактики и лечения сердечно-сосудистых заболеваний у пациентов пожилого возраста. Традиционно сердечно-сосудистая профилактика подразумевает коррекцию образа жизни (борьбу с гиподинамией, отказ от курения, диетические мероприятия) и лечение артериальной гипертензии (АГ), дислипидемии, сахарного диабета. Основной акцент сделан на тактике лечения АГ у пациентов пожилого возраста, представлен алгоритм ведения пожилых больных АГ на фоне сопутствующих заболеваний.

Литература


1. ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. J Am Coll Cardiol 2011;57(20):2037–114.
2. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985;1(8442):1349–54.
3. Boutitie F, Gueyffier F, Pocock S, et al. INDANA Project Steering Committee. INdividual Data ANalysis of Antihypertensive intervention. J-shaped relationship between blood pressure and mortality in hypertensive
patients: new insights from a meta-analysis of individual-patient data. Ann Intern Med 2002;136:438–48.
4. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J 1986;293: 1145–51.
5. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575–85.
6. Dahlof B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995–1003.
7. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOPHypertension). Lancet 1991;338:1281–85.
8. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1992; 339(8787):252.
9. Fagard RH, Staessen JA, Thijs L, et al. On-treatment diastolic blood pressure and prognosis in systolic Hypertension. Arch Intern Med 2007;67(17):1884–91.
10. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:175–76.
11. Kannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham study. Am J Cardiol 1971;27:335–46.
12. Kjeldsen SE, Dahlof B, Devereux RB, et al. LIFE (Losartan Intervention for Endpoint Reduction) Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricularhypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE)
substudy. JAMA 2002;288:1491–98.
13. Laher MS, Natin D, Rao SK, et al. Lisinopril in elderly patients with hypertension. J Cardiovasc Pharmacol 1987;9(3):69–71.
14. Lithell H, Hansson L, Skoog I, et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertens 2003;21:875–86.
15. Malacco E, Piazza S, Omboni S. Zofenopril Versus Lisinopril in the Treatment of Hypertension: Results. Clin Drug Invest 2005;25(3):175–82.
16. Marlier R, Vandepapeliere P, De Vriese G. Safety and efficacy of lisinopril in elderly patients with mild to moderate hypertension. J Hum Hypertens 1989;3(1):163–67.
17. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 1992;304(6824):405–12.
18. Messerli FH; Grossman E, Goldbourt U. Are β-Blockers Efficacious as First-line Therapy for Hypertension in the Elderly? JAMA 1998;279(23):1903–907.
19. Moser M. Hypertension Treatment and the Prevention of Coronary Heart Disease in the Elderly. Am Fam Physician 1999;59(5): 1248–56.
20. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Arch Intern Med 1992;152:56–64.
21. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255–64.
22. Somes GW, Pahor M, Shorr RI, et al. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med 1999;159:2004–09.
23. Staessen JA, Fagard R, Thijs L, et al. Morbidity and mortality in the placebocontrolled European Trial on Isolated Systolic Hypertension in the Elderly. Lancet 1997;350:757–64.
24. The ALLHAT Officers, Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel
blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981–97.
25. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157:2413–46.
26. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. Eur Heart J 2007;28:1462–536.
27. Кисляк О.А., Алиева А.М Возможности применения ингибитора ангиотензинпревращающего фермента лизиноприла для лечения артериальной гипертонии у пожилых людей // РМЖ 2005. № 11. С. 736–40.


Об авторах / Для корреспонденции


Напалков Д.А. – доцент, кандидат медицинских наук ГОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития РФ.
Головенко Е.Н. – кандидат медицинских наук ФГУ “Эндокринологический научный центр” Минздравсоцразвития РФ


Похожие статьи


Бионика Медиа